mTOR

Mammalian target of Rapamycin

mTOR

mTOR Isoform Specific Products:

mTOR Isoform Comparison

mTOR Related Products (341)
Antibodies (14)
mTOR Signaling Pathway
mTOR Isoform Comparison

By Effects:	Control (1) Inhibitors (288) Substrate (1) Antagonist (1) Activators (29) Modulators (6) p53 Inhibitor (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-N9942

Physalin A	Inhibitor	99.22%
Physalin A is a biologically active withanolide. Physalin A shows anti-inflammatory, antifibrotic and ameliorative effects on autophagy in models of disc degeneration. Physalin A has antitumor activity and can induce apoptosis, ROS production and G2/M phase cell cycle arrest. Besides. Physalin A can significantly increase the activity of quinone reductase and increase the expression of detoxifying enzymesc.

HY-10812

GNE-490	Inhibitor
GNE-490, a (thienopyrimidin-2-yl)aminopyrimidine, is a potent pan-PI3K inhibitor with IC₅₀s of 3.5 nM, 25 nM, 5.2 nM, 15 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively. GNE-490 has >200 fold selectivity for mTOR (IC₅₀=750 nM). GNE-490 shows potent suppression efficacy profile against MCF7.1 breast cancer xenograft model.

HY-134903

(32-Carbonyl)-RMC-5552	Inhibitor
(32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC₅₀s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2).

HY-137315

TML-6	Inhibitor	99.01%
TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloid precursor protein and β-amyloid (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-oxidative Nrf2 gene. TML-6 has the potential for Alzheimer’s disease (AD) research.

HY-139142

Simufilam	Inhibitor	98.08%
Simufilam (PTI-125) is an orally active FLNA modulator. Simufilam restores NMDAR signaling and Arc expression. Simufilam inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, improves insulin sensitivity, reduces Aβ₄₂-induced neuroinflammation and tau protein hyperphosphorylation. Simufilam can be used for research of Alzheimer's disease.

HY-124036

DS-7423	Inhibitor	99.75%
DS-7423 is a dual PI3K and mTOR inhibitor, with IC₅₀ values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity.

HY-10218S

Everolimus-d₄	Inhibitor
Everolimus-d₄ is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].

HY-N2590

Lupenone		99.74%
Lupenone is an orally active lupine-type triterpenoid that can be isolated from Musa basjoo. Lupenone Lupenone plays a role through the PI3K/Akt/mTOR and NF-κB signaling pathways. Lupenone has anti-inflammatory, antiviral, antidiabetic and anticancer activities.

HY-N6996R

Methyl Eugenol (Standard)	Inhibitor
Methyl Eugenol (Standard) is the analytical standard of Methyl Eugenol. This product is intended for research and analytical applications. Methyl Eugenol is a bait that has oral activity against oriental fruit fly (Hendel).Methyl Eugenol has anti-cancer and anti-inflammatory activities. Methyl Eugenol can induce Autophagy in cells. Methyl Eugenol can be used in the study of intestinal ischemia/reperfusion injury.

HY-141805

MHY-1685	Inhibitor	99.84%
MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.

HY-153120A

PI3K/mTOR Inhibitor-13 sodium	Inhibitor	98.13%
PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF).

HY-114267

Cbz-B3A	Inhibitor	≥98.0%
Cbz-B3A is a potent and selective inhibitor of mTORC1 signaling that appear to bind to ubiquilins 1, 2, and 4, and Cbz-B3A inhibits the phosphorylation of eIF4E-binding protein 1 (4EBP1).

HY-B1787

Sulindac sulfone	Inhibitor	98.10%
Sulindac sulfone is an mTORC1 pathway inhibitor and a metabolite of Sulindac. Sulindac sulfone inhibits colon cancer cell growth and induces cell cycle arrest. Sulindac sulfone is used in cancer research.

HY-17471AR

Metformin (hydrochloride) (Standard)	Inhibitor	99.97%
Metformin hydrochloride (Standard) is the analytical standard of Metformin (hydrochloride). This product is intended for research and analytical applications. Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo.

HY-162143

SKI-349	Inhibitor	99.58%
SKI-349 is a dual-targeted inhibitor of sphingosine kinase 1/2 (SPHK1/2) and microtubule assembly (MDA). SKI-349 has anticancer activity. SKI-349 can inhibit the vitality, invasion, and AKT/mTOR signaling pathway of liver cells.

HY-N10303

Withangulatin A	Inhibitor	99.76%
Withangulatin A is the inhibitor for COX-2. Withangulatin A inhibits MAPK, NF-κB, Akt/mTOR/p70S6K pathway, exhibits antitumor, anti-inflammatory and trypanocidal activities.

HY-N0486R

L-Leucine (Standard)	Activator
L-Leucine (Standard) is the analytical standard of L-Leucine. This product is intended for research and analytical applications. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.

HY-W654330

Pyraclostrobin-d₆
Pyraclostrobin-d₆ is deuterium-labeled Pyraclostrobin (HY-N6626).

HY-111065

OXA-01	Inhibitor
OXA-01 is a potent mTORC1 and mTORC2 inhibitor, with IC₅₀ values of 29 nM and 7 nM, respectively.

HY-147284

PI3K-IN-37	Inhibitor	≥99.0%
PI3K-IN-37 (Example 84.1) is a PI3K α/β/δ inhibitor with IC₅₀s of 6, 8, 4 nM, respectively. PI3K-IN-37 can also inhibit mTOR (IC₅₀=4 nM).

SLC7A5 SLC3A2 Sestrin1/2 CASTOR1 CASTOR1 GATOR2 GATOR1 FLCN-FNIP2 RagA/B RagC/D mTORC1 p14 MP1 p18 v-ATPase SLC38A9 Glucose GLUT4 DNA Damage p53 Sestrin1/2 AMPK IKKβ LKB1 RHEB FKBP12 Rapamycin mTOR mTORC1 DEPTOR RAPTOR PRAS40 mLST8 TNF Receptor TNF Growth factors GFRs: EGFRs, IGF1R, Insulin Receptor, FGFR and Met SOS SHC GRB2 IRS1 PI3K Ras Raf MEK ERK RSK TSC2 TSC1 TBC1D7 REDD1 4EBP eIF4E S6K eIF4B PDCD4 SKAR ATF4 MTHFD2 CAD HIF1α Lipin1 ULK1 UVRAG/
ATG14L TFEB ERK5 PGC1-α Autophage Proteasome
assembly SREBP Glucose
metabolism Apoptosis FOXO1,3 GRB10 S6K PTEN PDK1 Akt SGK Ion
transport Rho kinase PKC Actin/
cytoskeleton TSC2 TSC1 TBC1D7 mTOR DEPTOR RICTOR mSIN1 PROTOR mLST8 RAC1 GSK-3β Wnt mTORC2

Download mTOR Signaling Pathway Map.

The mammalian target of rapamycin (mTOR) signaling pathway integrates both intracellular and extracellular signals and serves as a central regulator of cell metabolism, growth, proliferation and survival^[1]. mTOR is the catalytic subunit of two distinct complexes called mTORC1 and mTORC2. mTORC1 comprises DEPTOR, PRAS40, RAPTOR, mLST8, mTOR, whereas mTORC2 comprises DEPTOR, mLST8, PROTOR, RICTOR, mSIN1, mTOR^[2]. Rapamycin binds to FKBP12 and inhibits mTORC1 by disrupting the interaction between mTOR and RAPTOR. mTORC1 negatively regulates autophagy through multiple inputs, including inhibitory phosphorylation of ULK1 and TFEB. mTORC1 promotes protein synthesis through activation of the translation initiation promoter S6K and through inhibition of the inhibitory mRNA cap binding 4E-BP1, and regulates glycolysis through HIF-1α. It promotes de novo lipid synthesis through the SREBP transcription factors. mTORC2 inhibits FOXO1,3 through SGK and Akt, which can lead to increased longevity. The complex also regulates actin cytoskeleton assembly through PKC and Rho kinase^[3].

Growth factors: Growth factors can signal to mTORC1 through both PI3K-Akt and Ras-Raf-MEK-ERK axis. For example, ERK and RSK phosphorylate TSC2, and inhibit it.

Insulin Receptor: The activated insulin receptor recruits intracellular adaptor protein IRS1. Phosphorylation of these proteins on tyrosine residues by the insulin receptor initiates the recruitment and activation of PI3K. PIP3 acts as a second messenger which promotes the phosphorylation of Akt and triggers the Akt-dependent multisite phosphorylation of TSC2. TSC is a heterotrimeric complex comprised of TSC1, TSC2, and TBC1D7, and functions as a GTPase activating protein (GAP) for the small GTPase Rheb, which directly binds and activates mTORC1. mTORC2 primarily functions as an effector of insulin/PI3K signaling.

Wnt: The Wnt pathway activates mTORC1. Glycogen synthase kinase 3β (GSK-3β) acts as a negative regulator of mTORC1 by phosphorylating TSC2. mTORC2 is activated by Wnt in a manner dependent on the small GTPase RAC1^[4].

Amino acids: mTORC1 senses both lysosomal and cytosolic amino acids through distinct mechanisms. Amino acids induce the movement of mTORC1 to lysosomal membranes, where the Rag proteins reside. A complex named Ragulator, interact with the Rag GTPases, recruits them to lysosomes through a mechanism dependent on the lysosomal v-ATPase, and is essential for mTORC1 activation. In turn, lysosomal recruitment enables mTORC1 to interact with GTP-bound RHEB, the end point of growth factor. Cytosolic leucine and arginine signal to mTORC1 through a distinct pathway comprised of the GATOR1 and GATOR2 complexes.

Stresses: mTORC1 responds to intracellular and environmental stresses that are incompatible with growth such as low ATP levels, hypoxia, or DNA damage. A reduction in cellular energy charge, for example during glucose deprivation, activates the stress responsive metabolic regulator AMPK, which inhibits mTORC1 both indirectly, through phosphorylation and activation of TSC2, as well as directly through the phosphorylation of RAPTOR. Sestrin1/2 are two transcriptional targets of p53 that are implicated in the DNA damage response, and they potently activate AMPK, thus mediating the p53-dependent suppression of mTOR activity upon DNA damage. During hypoxia, mitochondrial respiration is impaired, leading to low ATP levels and activation of AMPK. Hypoxia also affects mTORC1 in AMPK-independent ways by inducing the expression of REDD1, the protein products of which then suppress mTORC1 by promoting the assembly of TSC1-TSC2^[2].

Reference:

[1]. Laplante M, et al.mTOR signaling at a glance.J Cell Sci. 2009 Oct 15;122(Pt 20):3589-94.
[2]. Zoncu R, et al. mTOR: from growth signal integration to cancer, diabetes and ageing.Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35.
[3]. Johnson SC, et al. mTOR is a key modulator of ageing and age-related disease.Nature. 2013 Jan 17;493(7432):338-45.
[4]. Shimobayashi M, et al. Making new contacts: the mTOR network in metabolism and signalling crosstalk.Nat Rev Mol Cell Biol. 2014 Mar;15(3):155-62.

Rapamycin		mTOR, IC₅₀: 0.1 nM (in HEK293 cells )		99.94%
MHY1485		mTORC1	mTORC2	99.93%
Everolimus		mTOR, IC₅₀: 5-6 nM		99.85%
Torin 1	mTOR, IC₅₀: 3 nM	mTORC1, IC₅₀: 2-10 nM	mTORC2, IC₅₀: 2-10 nM	99.28%
AZD-8055	mTOR, IC₅₀: 0.8 nM			99.60%
Sapanisertib	mTOR, IC₅₀: 1 nM			99.66%
Salidroside	mTOR			99.90%
L-Leucine		mTORC1		99.79%
Temsirolimus		mTOR, IC₅₀: 1.76 μM		99.56%
Dactolisib	mTOR, IC₅₀: 20.7 nM			99.94%
Torin 2	mTOR, IC₅₀: 2.81 nM mTOR, EC₅₀: 0.25 nM (Cell Assay)			99.65%
PI-103		mTORC1, IC₅₀: 20 nM	mTORC2, IC₅₀: 83 nM	99.82%
RMC-5552		mTORC1		98.10%
Omipalisib		mTORC1, Ki: 0.18 nM	mTORC2, Ki: 0.3 nM	99.94%
RapaLink-1	mTOR			99.92%
Camonsertib	mTOR, IC₅₀: 120 nM			99.75%
Dihydromyricetin		mTORC1	mTORC2	99.73%
JR-AB2-011			mTORC2, IC₅₀: 0.36 μM	98.15%
3BDO	mTOR			99.93%
Torkinib	mTOR, IC₅₀: 8 nM	mTORC1, IC₅₀: 30 nM	mTORC2, IC₅₀: 58 nM	99.03%
Aloe emodin			mTORC2	98.32%
hSMG-1 inhibitor 11j	mTOR, IC₅₀: 50 nM			99.82%
Vistusertib	mTOR, IC₅₀: 2.81 nM			99.32%
Gedatolisib	mTOR, IC₅₀: 1.6 nM			99.68%
KU-0063794		mTORC1, IC₅₀: 10 nM	mTORC2, IC₅₀: 10 nM	99.67%
Paxalisib	mTOR, Ki: 70 nM			99.63%
PF-04691502	mTOR, Ki: 16 nM			99.91%
hSMG-1 inhibitor 11e	mTOR, IC₅₀: 45 nM			99.81%
Samotolisib	mTOR, IC₅₀: 165 nM			99.27%
Apitolisib	mTOR, Ki: 17 nM			99.29%
Bimiralisib	mTOR, IC₅₀: 89 nM			98.62%
CC-115	mTOR, IC₅₀: 21 nM			99.82%
Dactolisib Tosylate	mTOR, IC₅₀: 20.7 nM			99.87%
Voxtalisib	mTOR, IC₅₀: 157 nM	mTORC1, IC₅₀: 160 nM	mTORC2, IC₅₀: 910 nM	99.02%
Onatasertib	mTOR, IC₅₀: 16 nM			99.13%
BGT226	mTOR			99.51%
WYE-132	mTOR, IC₅₀: 0.19 nM			99.90%
mTOR inhibitor-3	mTOR, Ki: 1.5 nM			99.09%
PP121	mTOR, IC₅₀: 10 nM			98.67%
OSI-027	mTOR, IC₅₀: 4 nM	mTORC1, IC₅₀: 22 nM	mTORC2, IC₅₀: 65 nM	99.95%
Ridaforolimus		mTOR		99.75%
GSK1059615	mTOR, IC₅₀: 12 nM			≥99.0%
PKI-402	mTOR, IC₅₀: 3 nM			98.43%
VS-5584	mTOR, IC₅₀: 37 nM			99.14%
GNE-317	mTOR			99.14%
PI-103 Hydrochloride		mTORC1, IC₅₀: 20 nM	mTORC2, IC₅₀: 83 nM	98.55%
CZ415	mTOR, pIC₅₀: 8.07			98.39%
PQR530	mTOR, Kd: 0.33 nM			99.98%
ETP-46464	mTOR, IC₅₀: 0.6 nM			99.55%
(+)-Usnic acid		mTORC1	mTORC2	99.63%
Palomid 529		TORC1	TORC2	99.37%
CC-115 hydrochloride	mTOR, IC₅₀: 21 nM			98.03%
BGT226 maleate	mTOR			99.92%
GNE-493	mTOR, IC₅₀: 30 nM			99.81%
GDC-0349	mTOR, Ki: 3.8 nM			98.02%
PF-04979064	mTOR, Ki: 1.42 nM			99.54%
PQR620		mTORC1	mTORC2	98.01%
WAY-600	mTOR, IC₅₀: 9 nM			99.75%
NSC781406	mTOR, IC₅₀: 5.4 nM			99.97%
WYE-354	mTOR, IC₅₀: 5 nM			98.04%
PI3K/mTOR Inhibitor-2	mTOR, IC₅₀: 4.7 nM			99.10%
Hederacolchiside A1	mTOR			≥99.0%
HDACs/mTOR Inhibitor 1	mTOR, IC₅₀: 1.2 nM			99.01%
MTI-31	mTOR, Ki: 0.2 nM mTOR, IC₅₀: 39 nM (100 μM ATP)			99.98%
mTOR inhibitor-8	mTOR			98.14%
MT 63-78		mTORC1		98.50%
PI3K/mTOR Inhibitor-4	mTOR, IC₅₀: 13.85 nM
GNE-477	mTOR, Ki: 21 nM			98.75%
ETP-45658	mTOR, IC₅₀: 152.0 nM			98.97%
Rotundic acid	mTOR			99.41%
PKI-179	mTOR, IC₅₀: 0.42 nM			≥98.0%
Zederone	mTOR			99.61%
XL388	mTOR, IC₅₀: 9.9 nM			99.74%
FT-1518		mTORC1	mTORC2	98.62%
HTH-01-091	mTOR, IC₅₀: 632 nM			98.64%
AZD3147		mTORC1	mTORC2	99.93%
WYE-687	mTOR, IC₅₀: 7 nM			98.05%
PKI-179 hydrochloride	mTOR, IC₅₀: 0.42 nM			99.66%
CC214-2		mTORC1	mTORC2	98.41%
8-Aminoadenosine	mTOR			99.94%
GNE-490	mTOR, IC₅₀: 750 nM
TML-6	mTOR			99.01%
PI3K-IN-37	mTOR, IC₅₀: 4 nM			≥99.0%
Pomiferin	mTOR, IC₅₀: 6.2 μM			98.98%
PI3K-IN-22	mTOR, IC₅₀: 0.6 nM			99.50%
WYE-687 dihydrochloride	mTOR, IC₅₀: 7 nM			≥98.0%
Coronarin A		mTORC1		≥98.0%
PI3K-IN-18	mTOR, IC₅₀: 49 nM			≥99.0%
FD274	mTOR, IC₅₀: 2.03 nM			99.45%
PI3Kα/mTOR-IN-1	mTOR, Ki: 10.6 nM			99.30%
HSP90/mTOR-IN-1	mTOR, IC₅₀: 29 nM
PI3K/mTOR Inhibitor-1	mTOR, IC₅₀: 186 nM
mTOR inhibitor-2	mTOR, IC₅₀: 7 nM
PI3K/mTOR Inhibitor-9	mTOR, IC₅₀: 38 nM (phospho-S6 cellular assay) mTOR, IC₅₀: 16 nM (Ser240/244 cellular assay)
SN32976	mTOR, IC₅₀: 194 nM			99.49%
ATM Inhibitor-3	mTOR
ATM Inhibitor-4	mTOR
mTOR/HDAC-IN-1	mTOR, IC₅₀: 0.49 nM
PI3K/mTOR Inhibitor-3	mTOR
PI3Kα-IN-5	mTOR, IC₅₀: 3.3 nM
PI3K/mTOR Inhibitor-12	mTOR, IC₅₀: 3.12 nM
PI3K/mTOR Inhibitor-8	mTOR, IC₅₀: 12 nM
ATR-IN-20	mTOR, IC₅₀: 18 nM
Antifungal agent 106	mTOR, IC₅₀: 0.8 μM
PI3K/mTOR Inhibitor-14	mTOR, IC₅₀: 10.1 nM
mTOR/HDAC6-IN-1	mTOR, IC₅₀: 133.7 nM
mTOR inhibitor-13	mTOR, IC₅₀: 0.29 nM
mTOR inhibitor-17	mTOR, IC₅₀: 0.68 nM
mTOR inhibitor-16	mTOR, IC₅₀: 1.25 nM
mTOR inhibitor-10	mTOR, IC₅₀: 0.7 nM

Name
Email *

	Sorry, but the email address you supplied was invalid.

mTOR

mTOR

mTOR Isoform Specific Products:

mTOR Isoform Specific Products:

mTOR Related Products (341)

Antibodies (14)

mTOR Signaling Pathway

mTOR Isoform Comparison

mTOR Related Products (341):